TERT and hepatocellular carcinoma: TP53‐TERT aberrations were the most commonly detected co‐mutations (16/75, 21.3%) in non‐sarcomatoid HCC group, while (5/15, 33.3%) patients harbored TP53‐TERT co‐mutations in sarcomatoid HCC group (p = 0.316).